HER2-Positive Gastric Cancer: The Best Second-Line Drug Carries the One Risk This Patient Already Has
The drug with the clearest efficacy edge here also carries a specific lung toxicity, and this patient's chest CT already shows something that makes that risk harder to dismiss as background noise.
F.N., a 63-year-old woman, spent thirty years as an elementary school art teacher and has kept a pottery wheel in her garage since retiring, work she's continued through most of her cancer treatment. Her HER2-positive gastric adenocarcinoma, diagnosed fourteen months ago, responded well to first-line trastuzumab and chemotherapy for nine months before this month's scan confirmed progression in her liver metastases. The same scan, read carefully by radiology, also flagged incidental mild bibasilar reticular changes with a small amount of ground-glass opacity — asymptomatic, not present on her pre-treatment imaging fourteen months ago, and of uncertain significance: early interstitial change, prior chemotherapy-related pulmonary effect, or simply an incidental finding warranting nothing more than watchful follow-up.
Trastuzumab deruxtecan has shown a real, substantial response-rate advantage in HER2-positive gastric cancer progressing after prior trastuzumab-based therapy, including in DESTINY-Gastric02, and represents the single most effective second-line option available to her by response rate alone. It also carries a specific, well-documented risk of drug-related interstitial lung disease — not a generic chemotherapy pulmonary toxicity, but a defined adverse event requiring baseline and serial imaging surveillance precisely because early cases can progress to severe, occasionally fatal pneumonitis if unrecognized. Ramucirumab combined with paclitaxel, the other standard second-line option, does not carry that same specific pulmonary signal, though it lacks any HER2- directed mechanism and has shown a smaller response rate in this population. F.N.'s new, unexplained interstitial changes sit directly at the center of that tradeoff — not disqualifying by themselves, but no longer the clean baseline the drug's monitoring protocol was designed around. The reassuring facts cut less far than they look: she is a never-smoker with a normal oxygen saturation and no symptoms, which is exactly the profile in which a reticular abnormality gets called incidental — and also exactly the profile in which nothing on file explains why it appeared in the fourteen months since her last clean chest imaging.
Clinic visit, reviewing progression scan and incidental chest findings
Trastuzumab deruxtecan has the strongest efficacy data of any second-line option here — DESTINY-Gastric02 (Van Cutsem et al., Lancet Oncology 2023) is the Western-population trial behind that — and its monitoring protocol exists specifically because interstitial lung disease is a known, defined risk — not something we'd be discovering for the first time. Her new imaging finding is mild and she's asymptomatic. I'd rather start under close monitoring than delay her strongest option for something that may turn out to be incidental.
I'd push back on calling this a clean-enough baseline to start monitoring from. If we begin T-DXd now and her lungs change further in a month, we won't be able to tell whether we're seeing drug-related pneumonitis or the natural progression of whatever this pre-existing process already is — and that distinction matters enormously for whether we stop the drug immediately or manage it differently. A brief pulmonary function test and a focused high-resolution CT review, done in the next week, gives us an actual baseline to monitor against instead of an ambiguous one.
I'm not saying this finding rules the drug out — I'm saying starting without characterizing it first makes every future decision about her lungs harder, not easier.
While that workup happens, I don't think she needs to go untreated. Ramucirumab plus paclitaxel — the RAINBOW regimen (Wilke et al., Lancet Oncology 2014) — has a real, if smaller, response rate in this setting and no comparable pulmonary toxicity signal — it lets her start systemic therapy this week rather than waiting on pulmonology, and keeps trastuzumab deruxtecan available once her baseline lung status is actually characterized, rather than starting it on an incomplete picture.
Agreed: ramucirumab plus paclitaxel started this week, pulmonary function testing and dedicated high-resolution CT review completed within seven to ten days, and trastuzumab deruxtecan initiated promptly if that workup shows no active or high-risk pulmonary process.
Not fully agreed: the medical oncologist's preference for starting T-DXd immediately under close monitoring, rather than waiting on formal pulmonary workup, was recorded explicitly as a reasonable alternative not adopted — the group prioritized establishing a clean, characterized baseline over the several days' difference in treatment start, judging that gap acceptable given F.N.'s current asymptomatic status.